InvestorsHub on MSN
Beam Therapeutics shares climb after positive BEAM-302 trial update
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) gained about 8% on Wednesday after the company released updated results from its ongoing Phase 1/2 clinical study of BEAM-302, a treatment being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results